- Home
- TLPH vs AYTU Comparison
TLPH vs AYTU Comparison
Compare TLPH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- AYTU
- Stock Information
- Founded
- TLPH 2005
- AYTU N/A
- Country
- TLPH United States
- AYTU United States
- Employees
- TLPH N/A
- AYTU N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- AYTU Health Care
- Exchange
- TLPH Nasdaq
- AYTU Nasdaq
- Market Cap
- TLPH 10.6M
- AYTU 9.6M
- IPO Year
- TLPH 2011
- AYTU N/A
- Fundamental
- Price
- TLPH $0.45
- AYTU $2.39
- Analyst Decision
- TLPH Strong Buy
- AYTU Strong Buy
- Analyst Count
- TLPH 1
- AYTU 2
- Target Price
- TLPH $6.00
- AYTU $10.00
- AVG Volume (30 Days)
- TLPH 42.9K
- AYTU 669.1K
- Earning Date
- TLPH 08-13-2025
- AYTU 05-14-2025
- Dividend Yield
- TLPH N/A
- AYTU N/A
- EPS Growth
- TLPH N/A
- AYTU N/A
- EPS
- TLPH N/A
- AYTU N/A
- Revenue
- TLPH $27,000.00
- AYTU $81,659,000.00
- Revenue This Year
- TLPH N/A
- AYTU N/A
- Revenue Next Year
- TLPH $14,533.26
- AYTU $8.68
- P/E Ratio
- TLPH N/A
- AYTU $13.06
- Revenue Growth
- TLPH N/A
- AYTU 0.41
- 52 Week Low
- TLPH $0.43
- AYTU $0.95
- 52 Week High
- TLPH $1.19
- AYTU $2.96
- Technical
- Relative Strength Index (RSI)
- TLPH 45.62
- AYTU 70.58
- Support Level
- TLPH $0.45
- AYTU $2.04
- Resistance Level
- TLPH $0.52
- AYTU $2.40
- Average True Range (ATR)
- TLPH 0.03
- AYTU 0.14
- MACD
- TLPH -0.00
- AYTU 0.02
- Stochastic Oscillator
- TLPH 35.33
- AYTU 87.27
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.